HAYWARD, Calif., Nov. 11 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced new data on its lead product, varespladib (A-002) at the American Heart Association (AHA) Annual Conference in New Orleans, Louisiana. Anthera has completed two Phase II trials in varespladib for the treatment of coronary heart disease. At the AHA conference, Anthera and its collaborators released new data from the Phase II PLASMA-2 study, which examined varespladib (A-002) in patients with cardiovascular disease.
Results from the most recent study showed that in patients with coronary heart disease (CHD) currently on statin therapy:
-- Varespladib had a significant anti-inflammatory effect as measured by a greater than 20% relative reduction in C-reactive protein
-- Varespladib had a substantial reduction in the target enzyme and pro- inflammatory marker, secretory phospholipase A2 (84%, p<.0001)
-- Varespladib resulted in a significant reduction in LDL in CHD patients (15%, p=.0006)
-- Varespladib caused a significant reduction in small LDL particles in CHD patients
-- Varespladib established a once a day dosing schedule with a clearly defined dose response
-- Varespladib continued to have a strong safety profile, confirming results from previous studies
"We are pleased to confirm the anti-inflammatory effect and safety profile of varespladib in patients with CHD," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "The multiple therapeutic impact of varespladib's mechanism of action provides us with an opportunity to develop a first-in-class product targeting a life-threatening coronary event for which there are limited therapeutic options."
"Along with the Phase II PLASMA data presented at the American College
of Cardiology earlier this year, today's data at AHA
|SOURCE Anthera Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved